First People's Hospital

Tislelizumab combined with chemoradiotherapy is a Phase 2 immunoncology program targeting esophageal squamous cell carcinoma (ESCC), sponsored by The First People's Hospital of Lianyungang. Tislelizumab (TEVIMBRA) is a programmed cell death protein 1 (PD-1) inhibitor developed by BeiGene, which has achieved regulatory approval in Australia (April 2025) and the European Union (October 2025). The combination strategy leverages tislelizumab's immunomodulatory mechanism alongside conventional chemoradiotherapy to enhance treatment efficacy in ESCC patients. The program remains active as of September 2022, with clinical development ongoing under trial identifier NCT05547828. ESCC represents a significant unmet medical need, particularly in Asia-Pacific regions where incidence is highest. The regulatory approvals of tislelizumab in major markets underscore the therapeutic potential of PD-1 inhibition in oncology, positioning this combination approach as a clinically relevant strategy for improving outcomes in locally advanced or metastatic ESCC.

Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer mortality globally, with particularly high incidence in East Asia. Current standard-of-care chemoradiotherapy achieves modest survival outcomes, creating substantial unmet medical need for combination approaches that enhance therapeutic efficacy. Checkpoint inhibitor combinations with conventional therapies have demonstrated clinical benefit across multiple solid tumors, and ESCC represents a logical expansion opportunity given the immunogenic nature of the disease and the established safety profile of PD-1 inhibition.

Tislelizumab's regulatory approvals in Australia and the European Union validate its clinical utility and manufacturing standards, reducing development risk for combination programs. The PD-1 inhibitor class has transformed oncology treatment paradigms, and combination strategies with chemoradiotherapy are increasingly recognized as standard-of-care in multiple malignancies. The ESCC patient population, particularly in Asia-Pacific markets where disease burden is highest, represents a commercially significant opportunity. Success of this program could establish a new treatment standard for locally advanced ESCC and support label expansions or additional combination studies. The competitive landscape includes multiple approved antineoplastic agents, but few specifically optimized for ESCC in combination with chemoradiotherapy, positioning this program as potentially differentiated.

Drug Class: Monoclonal antibody immunomodulator (checkpoint inhibitor)

Mechanism of Action: Programmed cell death protein 1 (PD-1) inhibitor

Molecular Modality: Biologic (monoclonal antibody); note that the facts incorrectly classify this as 'small_molecule'—tislelizumab is a biologic

Target: Programmed cell death protein 1 (PD-1)

Therapeutic Class: Antineoplastic and immunomodulating agents (ATC L01)

Route of Administration: Not yet disclosed in available facts

Brand Name: TEVIMBRA

Regulatory Status: Approved in Australia (April 2025, PBS codes 14756P, 14765D) and European Union (October 2025, EMA product numbers EMEA/H/C/005542, EMEA/H/C/005919)

Developer: BeiGene (marketing authorization holders: BeiGene Ireland Ltd, Beone Medicines Ireland Limited in EU; BEONE MEDICINES AUS PTY LTD in Australia)

Related Therapies: Other PD-1 inhibitors in clinical development for ESCC and other malignancies; combination with chemoradiotherapy represents a multimodal approach

• Australia (TGA): Tislelizumab (TEVIMBRA) approved and listed on the Australian Register of Therapeutic Goods (ARTG) effective 1 April 2025. Sponsor: BEONE MEDICINES AUS PTY LTD. PBS codes: 14756P, 14765D.
• European Union (EMA): Tislelizumab (TEVIMBRA) granted European marketing authorization on 24 October 2025. Marketing authorization holders: BeiGene Ireland Ltd and Beone Medicines Ireland Limited. EMA product numbers: EMEA/H/C/005542, EMEA/H/C/005919.
• China (NMPA): Tislelizumab in clinical trials; multiple NCT identifiers indicate ongoing Phase 2/3 studies (NCT03941873, NCT04693234, NCT05314101, NCT05595590, NCT05620498, NCT05675813, NCT05681390, NCT05833984, NCT06097962, NCT06235918). Regulatory approval status in China not yet disclosed.
• FDA (United States): Regulatory status not yet disclosed in available facts.
• PMDA (Japan): Regulatory status not yet disclosed in available facts.
• Program-Specific (TD-CR-ESCC): Phase 2 status as of September 2022. Expected next milestone and regulatory pathway not yet disclosed. Pivotal trial NCT identifiers not yet disclosed.

• Strategic Positioning: The combination of tislelizumab with chemoradiotherapy represents a rational multimodal approach for ESCC, leveraging immunomodulation to enhance conventional cytotoxic therapy. The regulatory approvals of TEVIMBRA in Australia and the EU validate the drug's clinical profile and manufacturing standards, reducing development risk for this combination program.
• Unmet Medical Need: ESCC carries high mortality, particularly in Asia-Pacific regions. Current chemoradiotherapy outcomes are suboptimal, creating substantial opportunity for combination strategies that improve survival and quality of life.
• Clinical Development Status: The program remains in Phase 2 as of September 2022. The absence of disclosed efficacy data, safety profiles, or next milestone timelines limits assessment of clinical progress. Continued enrollment and data maturation are expected.
• Competitive Implications: Few approved therapies specifically target ESCC in combination with chemoradiotherapy. The PD-1 inhibitor class has demonstrated clinical benefit across multiple malignancies, positioning tislelizumab as a potentially differentiated option if efficacy and safety are favorable.
• Regulatory Pathway: Approvals in Australia and the EU establish precedent for regulatory acceptance of TEVIMBRA. Future catalysts include Phase 2 data readout, potential Phase 3 initiation, and regulatory submissions in additional markets (China, potentially FDA).
• Commercial Significance: ESCC represents a significant patient population in Asia-Pacific markets. Success of this program could support label expansion, establish a new treatment standard, and drive market adoption in high-incidence regions.